Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer

Journal: Science Translational Medicine

Published: 2019-12-04

DOI: 10.1126/scitranslmed.aax0428

Affiliations: 21

Authors: 33

Go to article
Institutions Share
Duke Department of Pathology, United States of America (USA) 0.39
Ambry Genetics, United States of America (USA) 0.18
UCLA Department of Microbiology, Immunology and Molecular Genetics (MIMG), United States of America (USA) 0.10
UCLA Department of Molecular, Cell, and Developmental Biology (MCDB), United States of America (USA) 0.04
First Affiliated Hospital, AHMU, China 0.03
Duke School of Nursing, United States of America (USA) 0.03
Duke Department of Surgery, United States of America (USA) 0.03
UCLA Division of Hematology/Oncology, United States of America (USA) 0.03
UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research (BSCRC), United States of America (USA) 0.02
UCLA Department of Urology, United States of America (USA) 0.02
UC Davis Comprehensive Cancer Center, United States of America (USA) 0.02
UC Davis Department of Urology, United States of America (USA) 0.02
Zhejiang Provincial People's Hospital, China 0.02
UCLA Molecular Biology Institute (MBI), United States of America (USA) 0.02
Duke Division of Medical Oncology, United States of America (USA) 0.02
Duke Cancer Institute (DCI), United States of America (USA) 0.02
The First Hospital of China Medical University, China 0.01
College of Basic Medical Science, CMU, China 0.01
UCLA Department of Molecular and Medical Pharmacology (DMMP), United States of America (USA) 0.01
VA Greater Los Angeles Healthcare System, United States of America (USA) 0.01

Return